Foghorn Therapeutics Inc.
News
Petri Dish: Dyne's Duchenne data; Foghorn hires BMS leader
BizJournals.com - Nat'l Business News This week there is new Duchenne data from Dyne Therapeutics, additional funding going to Somite Therapeutics and a new Bristol Myers Squibb leader headed to Foghorn Therapeutics.\n more…
Foghorn Therapeutics (NASDAQ:FHTX) Coverage Initiated at Jefferies Financial Group
Ticker Report Research analysts at Jefferies Financial Group assumed coverage on shares of Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) in a research report issued on Tuesday, MarketBeat Ratings reports...\n more…
Foghorn Therapeutics (NASDAQ:FHTX) Receives New Coverage from Analysts at Jefferies Financial Group
Zolmax Jefferies Financial Group assumed coverage on shares of Foghorn Therapeutics (NASDAQ:FHTX - Free Report) in a research note released on Tuesday, MarketBeat reports. The firm issued a buy rating and a...\n more…
Wall Street Analysts Think Foghorn Therapeutics Could Surge 81.16%: Read This Before Placing a Bet
Benzinga Foghorn Therapeutics Inc. (NASDAQ: FHTX) closed the last trading session at $8.28, gaining 35.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide.\n more…
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
Globe Newswire CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious...\n more…
Innovative Cancer Treatments Propel Foghorn Therapeutics' Growth Potential: Analyst Buy Rating Justified
TipRanks Financial Blog Kelly Shi, an analyst from Jefferies, has initiated a new Buy rating on Foghorn Therapeutics (FHTX). Kelly Shi's rating is based on the innovative ...\n more…